It became clear over the first quarter that the amount of business that had gone to the compounders was just significantly ...

Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.

Hims & Hers Health shows impressive operating leverage and a scalable business model, with massive growth potential from new ...

Shares in Novo Nordisk were still up after Q1 2025 witnessed a total revenue jump by 18%, compared to Q1 2024.

As of 11:20 a.m. ET, Hims & Hers stock is surging to 11.2% and beyond, whereas both Eli Lilly and Novo Nordisk stocks are down 3.2%. Hims & Hers reported a surge in sales in the first quarter of ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is losing ground.

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic Wegovy.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...

Nader Kabbani, who led the launch of Amazon Pharmacy and the acquisition of PillPack, will take the chief operating officer ...